These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1116 related items for PubMed ID: 19438397

  • 41. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
    Barrios A, Negredo E, Domingo P, Estrada V, Labarga P, Asensi V, Morales D, Santos J, Clotet B, Soriano V, EFADITE Study Group.
    Antivir Ther; 2005; 10(7):825-32. PubMed ID: 16312178
    [Abstract] [Full Text] [Related]

  • 42. Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study.
    Manosuthi W, Tantanathip P, Chimsuntorn S, Eampokarap B, Thongyen S, Nilkamhang S, Sungkanuparph S.
    Int J Infect Dis; 2010 Nov; 14(11):e1013-7. PubMed ID: 20880733
    [Abstract] [Full Text] [Related]

  • 43. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J.
    Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
    [Abstract] [Full Text] [Related]

  • 44. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    Mankhatitham W, Lueangniyomkul A, Manosuthi W.
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):651-8. PubMed ID: 21706943
    [Abstract] [Full Text] [Related]

  • 45. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
    Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM, Flynn PM.
    N Engl J Med; 1999 Dec 16; 341(25):1874-81. PubMed ID: 10601506
    [Abstract] [Full Text] [Related]

  • 46. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
    Keiser P, Nassar N, White C, Koen G, Moreno S.
    HIV Clin Trials; 2002 Dec 16; 3(4):296-303. PubMed ID: 12187503
    [Abstract] [Full Text] [Related]

  • 47. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S, Yeni PG, Bouchaud O, Costagliola D, Clinical Epidemiology Group from the French Hospital Database on HIV.
    AIDS; 2006 Oct 24; 20(16):2099-106. PubMed ID: 17053356
    [Abstract] [Full Text] [Related]

  • 48. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.
    Pérez-Elías MJ, Moreno A, Moreno S, López D, Antela A, Casado JL, Dronda F, Gutiérrez C, Quereda C, Navas E, Abraira V, Rodríguez MA.
    HIV Clin Trials; 2005 Oct 24; 6(6):312-9. PubMed ID: 16452065
    [Abstract] [Full Text] [Related]

  • 49. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T, Ananworanich J, Chetchotisakd P, Kantipong P, Jirajariyavej S, Sirivichayakul S, Munsakul W, Prasithsirikul W, Sungkanuparph S, Bowonwattanuwong C, Klinbuayaem V, Petoumenos K, Hirschel B, Bhakeecheep S, Ruxrungtham K.
    Antivir Ther; 2011 Oct 24; 16(7):1113-21. PubMed ID: 22024527
    [Abstract] [Full Text] [Related]

  • 50. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
    DeJesus E, McCarty D, Farthing CF, Shortino DD, Grinsztejn B, Thomas DA, Schrader SR, Castillo SA, Sension MG, Gough K, Madison SJ, EPV20001 International Study Team.
    Clin Infect Dis; 2004 Aug 01; 39(3):411-8. PubMed ID: 15307010
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E, Bini T, Adorni F, Capetti A, Rizzardini G, Faggion I, Mussini C, Sollima S, Melzi S, Bongiovanni M, Tordato F, Cicconi P, Castelnuovo B, Rusconi S, d'Arminio Monforte A.
    Antivir Ther; 2003 Feb 01; 8(1):27-35. PubMed ID: 12713061
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.
    Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, Gibert C, Rodriguez-Barradas M, Mole L, Justice AC.
    AIDS; 2007 Jul 31; 21(12):1579-89. PubMed ID: 17630553
    [Abstract] [Full Text] [Related]

  • 56. Successful viral suppression with subsequent efavirenz-based regimen in HIV-1-infected patients who stop nevirapine prior to discontinuation of the NRTI backbone.
    Chimsuntorn S, Sungkanuparph S, Manosuthi W.
    J Int Assoc Physicians AIDS Care (Chic); 2010 Jul 31; 9(1):43-5. PubMed ID: 20071597
    [Abstract] [Full Text] [Related]

  • 57. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW, AIDS Clinical Trials Group 398 Study Team.
    JAMA; 2002 Jul 10; 288(2):169-80. PubMed ID: 12095381
    [Abstract] [Full Text] [Related]

  • 58. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W, Chokephaibulkit K.
    Int J Infect Dis; 2008 Nov 10; 12(6):e33-8. PubMed ID: 18573672
    [Abstract] [Full Text] [Related]

  • 59. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
    Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fätkenheuer G, Lundgren JD, Mocroft A, EuroSIDA study group.
    HIV Med; 2011 May 10; 12(5):259-68. PubMed ID: 20812948
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 56.